Back to top

Gilead Sciences, Inc. (GILD)

(Real Time Quote from BATS)

$80.91 USD


+1.42 (1.79%)

Updated Feb 23, 2018 03:58 PM ET

Add to portfolio

4-Sell       4  

A Value | D Growth | C Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva

Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.


Zacks Equity Research

Intercept Starts OCA Trial for NASH Patients With Cirrhosis

Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.


Zacks Equity Research

3 ETFs to Watch on Biotech Earnings

Major Biotech companies report mixed Q4 results.


Zacks Equity Research

Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.


Zacks Equity Research

Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.


Zacks Equity Research

FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.


Zacks Equity Research

Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.


Mark Vickery

New Quarterly Earnings Results for DIS, CMG, SNAP and More

Will these companies reporting after the close -- DIS, CMG, SNAP and GILD -- catch a break in after-hours trading?


Madeleine Johnson

Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline

Gilead Sciences (GILD) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.


Zacks Equity Research

Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.


Zacks Equity Research

Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.


Arpita Dutt

Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.


Arpita Dutt

Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February

Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.


Zacks Equity Research

Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.


Zacks Equity Research

Bluebird Up on Buyout Speculation After Celgene/Juno Deal

Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.


Zacks Equity Research

Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.


Sweta Killa

Healthcare ETFs to Watch As Q4 Earnings Unfold

With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.


Zacks Equity Research

Gilead Collaborates with Pfizer for Yescarta Combo Study

Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.


Arpita Dutt

Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion

Focus this week was on Merck's (MRK) data on Keytruda as well as Novartis's updates on Kymriah and its biosimilar efforts.


Zacks Equity Research

Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.


Zacks Equity Research

Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.


Arpita Dutt

3 Top-Ranked Drug Stocks that are Broker Favorites

With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.


Mark Vickery

Top Research Reports for Apple, JPMorgan & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV).


Zacks Equity Research

Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.


Arpita Dutt

Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.


Zacks Equity Research

Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.


Zacks Equity Research

Big Pharma CEOs Speak About Impact of Tax Reform on M&A

This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.


Arpita Dutt

Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.


Arpita Dutt

FDA Approvals Surge in 2017: Here's a Look at the Numbers

There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.


Zacks Equity Research

Galapagos Reports Topline Data From Osteoarthritis Study

Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.